MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on Haystack MRD® Technology from Quest Diagnostics®

Blood test to aid cancer treatment and recurrence monitoring now available from a German lab for potentially faster results

HAMBURG, Germany, Oct. 17, 2025 /PRNewswire/ -- MVZ HPH Institute for Pathology and Hematopathology GmbH, today announced the availability of HPH MRD, a new tumor-informed circulating-tumor DNA (ctDNA) blood test for detecting minimal residual disease (MRD) in patients diagnosed with solid tumor cancers. The HPH MRD test is an in-house test manufactured by HPH that makes use of Haystack MRD technology and is available through a license from Haystack Oncology, a subsidiary of Quest Diagnostics® (NYSE: DGX), which developed and provides the Haystack MRD in-house developed test in the United States. The technology was purpose-built to detect ultralow levels of ctDNA with exceptional sensitivity and specificity, enabling the reliable identification of residual or recurrent disease.

Read more at prnewswire.com